Bristol-Myers Squibb

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Bristol-Myers Squibb sits in the top decile of US sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count).

1,025 total trials 73 currently recruiting 789 completed early-phase tilt top decile by trial count

Bristol-Myers Squibb: 1,025 sponsored US clinical trials, 73 recruiting.

Bristol-Myers Squibb sponsors 1,025 registered US clinical trials on ClinicalTrials.gov, 73 of them currently recruiting, and 789 completed. 242 of these trials are in Phase 3-4 (later-stage) and 675 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 20 trials.

Top-decile sponsor footprint

Bristol-Myers Squibb ranks in the top decile of sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

789 of 892 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,025 total, page 18 of 21

COMPLETED Phase 4

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

NCT00371150
COMPLETED Phase 3

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

NCT00371683
COMPLETED Phase 1

Bioequivalence Study of Atazanavir 300 mg Capsule

NCT00393328
TERMINATED Phase 2

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

NCT00388609
COMPLETED

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

NCT00382668
COMPLETED

Abatacept Pregnancy Exposure Registry

NCT01087125
COMPLETED Phase 1

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

NCT00362726
COMPLETED Phase 1

A Study of the Alternative Administration of Ixabepilone and Vinflunine

NCT00362830
COMPLETED Phase 1

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
COMPLETED Phase 3

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155
COMPLETED Phase 1

A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

NCT00329004
COMPLETED Phase 2

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

NCT00779428
COMPLETED Phase 1

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

NCT00357188
COMPLETED Phase 1

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

NCT00357604
TERMINATED Phase 2

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

NCT00359450
COMPLETED Phase 1

Atazanavir Twice Daily

NCT00357721
COMPLETED Phase 1

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716
COMPLETED Phase 2

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

NCT00320255
COMPLETED Phase 1

Drug Interaction Study With Proton Pump Inhibitor

NCT00357240
COMPLETED Phase 2

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

NCT00162123
COMPLETED Phase 2

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300
COMPLETED Phase 1

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

NCT00326586
COMPLETED Phase 2

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT00289627
COMPLETED Phase 1

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

NCT00365339
COMPLETED Phase 2

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT00289640
TERMINATED Phase 1

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

NCT00326131
TERMINATED Phase 1

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

NCT00300027
COMPLETED Phase 2

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

NCT00298987
COMPLETED Phase 1

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

NCT00803556
COMPLETED Phase 1

A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis

NCT00295282
COMPLETED Phase 1

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00323882
COMPLETED Phase 1

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

NCT00207051
COMPLETED Phase 1

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
COMPLETED Phase 2

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

NCT00135408
COMPLETED Phase 1

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344
TERMINATED Phase 1

Study of BMS-663513 in Patients With Advanced Cancer

NCT00309023
COMPLETED Phase 2

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005
COMPLETED Phase 1

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

NCT00135421
COMPLETED Phase 3

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

NCT00272779
COMPLETED Phase 1

Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

NCT00162292
COMPLETED Phase 2

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

NCT00284804
COMPLETED Phase 1

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

NCT00261365
COMPLETED Phase 1

ATV/Ritonavir Nevirapine Interaction (USPAC)

NCT00162149
COMPLETED Phase 1

Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

NCT00388557
COMPLETED Phase 2

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

NCT00119678
COMPLETED Phase 3

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808
TERMINATED Phase 1

Study of Dasatinib in Patients With Advanced Solid Tumors

NCT00162214
COMPLETED Phase 2

MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00112580
COMPLETED Phase 4

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

NCT00135356
COMPLETED Phase 3

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382
← Previous Page 18 of 21 Next →

Phase Distribution

PhaseTrial count
Phase 1 436
Phase 2 239
Phase 3 213
Phase 4 29

Therapeutic Areas

HIV Infections 20
Melanoma 14
Healthy Participants 13
Multiple Myeloma 10
Healthy Volunteers 9
Rheumatoid Arthritis 9
Psoriasis 8
Non-Small Cell Lung Cancer 7
Systemic Lupus Erythematosus 6
Carcinoma, Non-Small Cell Lung 5

What is open in the Bristol-Myers Squibb pipeline

73 recruiting of 1,025 indexed (7% open); 789 completed (77%).

Phase mix: 242 late (III/IV) vs 675 early (I/II) (early-phase heavy).

Top condition: HIV Infections (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Bristol-Myers Squibb: open-pipeline peers nationwide

Peers matched on 1,025 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20% Total trials Recruiting share Bristol-Myers SquibbUniversity of Wisconsin, MadisonUniversity of WashingtonUniversity of MinnesotaColumbia UniversityCarol Fabian, MDCelldex TherapeuticsKaiser PermanenteMannkind Corporation
Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,025 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bristol-Myers Squibb page

1,025 registered trials is a research-attention snapshot, not an endorsement of Bristol-Myers Squibb or any single study.

  • 73 of Bristol-Myers Squibb's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV Infections is the condition Bristol-Myers Squibb studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bristol-Myers Squibb pipeline card: 1,025 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.